Skip to main content
. 2014 Dec 10;65(1):101–107. doi: 10.1161/HYPERTENSIONAHA.114.04035

Figure 3.

Figure 3.

Mean (SE) values at baseline, during droxidopa administration, and after withdrawal for (A) dizziness/lightheadedness score (item 1 of the Orthostatic Hypotension Symptom Assessment Questionnaire, n=101) and (B) standing systolic blood pressure (SBP, n=100). Dashed lines denotes mean baseline values for reference; in a withdrawal design, the placebo group is expected to return to baseline.